Substance P: A Literature Course on What It Is and What Studies Report

This page is a structured reading course on Substance P, built from a fixed list of published papers. It describes what those papers reported, in what models, and with what limits. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication, or research participation. Nothing here is a protocol, a recommendation, or a statement about what any individual should do.

Module 1: What Substance P Is and How It Has Been Studied

Definition and class

Substance P is a neuropeptide of the tachykinin family, described in the review literature as an eleven-amino-acid peptide that acts preferentially at the neurokinin-1 (NK-1) receptor, a G-protein-coupled receptor (PMID 35806893). A 2022 review of its regenerative biology likewise characterised Substance P as a tachykinin peptide that engages NK-1 receptors on neuronal, immune, endothelial and stem-cell populations (PMID 35054936). Unlike synthetic research peptides designed in a laboratory, Substance P is an endogenous signalling molecule: it is produced by the body itself, which is why most of the literature studies its native release, its receptor, or drugs that block that receptor.

Origin and where it is found

Reviews place Substance P in both the central and the peripheral nervous system, with particularly well-described expression in small-diameter sensory neurons, and with additional sources in immune and epithelial cells (PMID 35806893). Work on the airway described Substance P as part of the sensory innervation and defence signalling of the respiratory tract, and discussed its possible relevance to neurological manifestations reported after COVID-19 infection (PMID 36949854). In the basal ganglia, researchers reported that Substance P participates in synaptic transmission in striatal neurons (PMID 30803756).

How it has been studied

Four broad approaches appear across the cited papers:

• Receptor-blockade studies, in which NK-1 receptor antagonists were used to infer what endogenous Substance P does, as reviewed for infectious and neurodegenerative central nervous system disease (PMID 27430034).
• Circuit and electrophysiology studies in animal tissue, such as the striatal synaptic transmission work (PMID 30803756).
• Behavioural neuroscience in mice, such as a study of Substance P in the lateral hypothalamic area and binge-like eating behaviour (PMID 41802059).
• Analytical and biochemical work, including the use of labelled Substance P as a reporter substrate to measure peptidase enzyme activity (PMID 31718985).

Limits of the evidence in Module 1: the definitional material above comes largely from narrative reviews rather than systematic reviews, so selection of supporting studies was at the authors' discretion. The cited sources describe where Substance P is expressed and what receptor it prefers; they do not establish a single, agreed functional role, and one review explicitly framed the peptide as "friend or foe" because its reported actions differ by tissue and context (PMID 35806893).

Module 2: Mechanism as Described in the Literature

Receptor signalling

The mechanistic core described across reviews is NK-1 receptor activation. A 2022 overview reported that Substance P binding to NK-1 receptors couples to intracellular signalling that can drive pro-inflammatory gene expression, vascular permeability and immune-cell recruitment, and that these same pathways have been linked to tissue repair in other contexts (PMID 35806893). The regenerative review described NK-1 receptor engagement on endothelial and progenitor cells as the proposed basis for reported effects on angiogenesis and wound repair (PMID 35054936).

Neurogenic inflammation and mast cells

A review of peripheral sympathetic neuromediation reported an interrelation between Substance P and histamine, including the capacity of Substance P to interact with mast-cell–derived histamine signalling in peripheral tissue (PMID 32787755). This mast-cell axis is the mechanism most often invoked when the literature describes flare, oedema and itch responses attributed to Substance P release.

Pain signalling — a contested mechanism

A 2019 Neuron commentary revisited the long-standing assumption that Substance P is a straightforward transmitter of inflammatory pain, and the authors argued that the field had been simultaneously right and wrong about its role, in light of newer circuit-level data (PMID 30731054). That framing matters: the failure of NK-1 antagonists as broad analgesics is part of why the mechanistic picture was re-examined, and a 2025 migraine paper proposed revisiting Substance P using methodology modelled on the anti-CGRP and anti-PACAP programmes (PMID 39891050).

Autonomic and respiratory control

A 2020 review examined whether serotonin and Substance P act in synergy or in competition in the control of breathing, reporting that both neuromodulators converge on respiratory rhythm-generating networks (PMID 32145695). Separate work described Substance P within the defence line of the respiratory tract (PMID 36949854).

Limits of the evidence in Module 2: mechanism papers here are predominantly reviews and preclinical studies. Receptor-level descriptions derived from cell and animal systems do not demonstrate that the same sequence occurs at the same magnitude in humans, and the pain literature shows that a mechanism can be widely accepted for decades and still require revision (PMID 30731054).

Module 3: Reported Outcomes by Study

The table below summarises what each cited paper studied and what it reported. No dose figures are listed because the verified source set used for this page does not supply them; where a paper's abstract did not state a quantity, the quantity is omitted rather than estimated.

Reading the outcome literature carefully

Two of the strongest experimental signals in this set are behavioural and electrophysiological rather than clinical: the mouse feeding study localised a Substance P action to the lateral hypothalamic area (PMID 41802059), and the striatal work situated it in synaptic transmission (PMID 30803756). The wound-healing result is notable because it was a combination effect: the study reported synergy between Substance P and thiorphan rather than an effect of the peptide alone (PMID 30603394).

Limits of the evidence in Module 3: these are animal, tissue and review-level outcomes. None of the cited outcome studies is a randomised controlled trial of Substance P administration in humans, endpoints differ so much between papers that they cannot be pooled, and a positive finding in one model does not predict any outcome in another species, tissue or disease.

Module 4: Substance P Side Effects: What Studies Report

The cited literature does not contain a human safety dataset for administered Substance P. What it does report is adverse biology attributed to Substance P signalling, which is a different kind of evidence and is presented as such below.

• Pro-inflammatory and potentially injurious signalling. A 2022 review titled "Substance P — Friend or Foe" reported that the same NK-1-mediated pathways associated with repair are also associated with inflammation, pain and disease progression depending on context (PMID 35806893).
• Inflammatory pain. Researchers described Substance P's involvement in inflammatory pain signalling and reported that the field's interpretation of that involvement required correction (PMID 30731054).
• Histamine-linked peripheral responses. A review reported an interrelation between Substance P and histamine as a peripheral sympathetic neuromediator, the axis conventionally linked to flare, swelling and itch (PMID 32787755).
• Neuroinflammation. A review of NK-1 receptor antagonists reported Substance P involvement in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system (PMID 27430034).
• Respiratory and post-viral neurological context. Authors discussed Substance P in respiratory tract defence and in neurological manifestations reported after COVID-19 infection (PMID 36949854).
• Headache biology. A 2025 review reported continued interest in Substance P as a mediator relevant to migraine pathophysiology (PMID 39891050).

Limits of the evidence in Module 4: disease association is not the same as a documented adverse-event rate. The cited papers did not report incidence figures, dose-related toxicity, severity grading or withdrawal rates for Substance P given as an intervention in people, and no long-term human safety follow-up appears in this source set. Any statement about how frequently a given effect would occur is therefore unsupported by these references.

Module 5: Pharmacokinetics Where Data Exist

Formal human pharmacokinetic parameters — bioavailability, volume of distribution, clearance, half-life — are not reported in the papers verified for this page, so none are stated here. What the set does cover is enzymatic handling.

A 2020 analytical study used labelled Substance P as a neuropeptide reporter substrate to quantify enzyme activity, which depends on the peptide being cleaved by peptidases in a measurable way (PMID 31718985). Indirect evidence for the importance of peptidase degradation also comes from the wound-healing study, in which researchers reported that combining Substance P with thiorphan — a peptidase inhibitor — synergically enhanced angiogenesis, implying that limiting enzymatic breakdown altered the observed response (PMID 30603394). Reviews of regenerative applications similarly discussed delivery and stability as practical obstacles in Substance P research (PMID 35054936).

Limits of the evidence in Module 5: an enzyme-activity assay is not a pharmacokinetic study. The cited work establishes that Substance P is a peptidase substrate; it does not establish plasma half-life, tissue distribution, route comparisons, or accumulation behaviour in humans, and those values are omitted here rather than inferred.

Module 6: Regulatory Status

Stated factually, and not as legal advice:

1. Substance P itself is not an approved drug product in the United States or the European Union. It appears in the literature as an endogenous peptide, a laboratory reagent and an experimental probe — for example as a labelled reporter substrate in assay development (PMID 31718985).
2. Research-use-only (RUO) status applies to Substance P material supplied for laboratory work. RUO labelling means the material is not intended for diagnostic or therapeutic use in humans or animals, and RUO status carries no assurance of identity, purity, sterility or endotoxin content for human exposure.
3. Its receptor is a drugged target. The pharmacological programme built around Substance P has centred on NK-1 receptor antagonists rather than on giving the peptide, and reviews have summarised that antagonist literature in central nervous system disease (PMID 27430034). Approved NK-1 antagonist medicines exist in the antiemetic category; they are distinct products with their own labelling and are not Substance P.
4. Compounding. In the United States, a substance must generally be the subject of an approved application, appear in a USP/NF monograph, or be listed on the relevant FDA bulk drug substances list to be eligible for pharmacy compounding under sections 503A/503B. Substance P is not an approved active ingredient, and eligibility determinations are made by regulators, not by researchers or writers.

Limits of the evidence in Module 6: regulatory classification changes over time and differs by country. This module describes categories, not the status of any particular supplier's material, and it is not legal advice; questions about lawful handling belong with a qualified professional and the current text of the applicable regulation.

What the Studies Did Not Test

Across the papers cited on this page, the following were not examined:

• Human dosing. No cited paper reported a dose, schedule or route for administering Substance P to people, and none is given here.
• Long-term safety. No cited paper followed human participants over months or years after Substance P exposure.
• Healthy-population use. The mouse feeding study addressed binge-like eating behaviour in mice (PMID 41802059); it did not test appetite or body-weight outcomes in healthy humans.
• Cosmetic or wound outcomes in humans. The angiogenesis finding was reported in a wound-healing research model with thiorphan co-administration (PMID 30603394), not in a clinical wound-care trial.
• Head-to-head comparisons. No cited paper compared Substance P against an approved medicine for the same endpoint.
• Drug interactions, pregnancy, paediatric or renal/hepatic-impairment populations. These appear nowhere in the verified set.
• Migraine outcomes. The 2025 paper proposed a methodological approach for re-examining Substance P in migraine; it reported a research strategy rather than trial results (PMID 39891050).

The honest summary of this literature is that Substance P is a well-characterised endogenous neuropeptide with a contested and context-dependent functional profile — described by one review as both friend and foe (PMID 35806893) — and that the experimental work sits overwhelmingly in animal, tissue and review territory. Again: this page is educational only and is not medical advice; a licensed physician is the appropriate source for individual guidance.

References

• Substance P-Friend or Foe (Journal of Clinical Medicine, 2022)
• Substance P in the lateral hypothalamic area regulates binge-like eating behaviors in mice (PNAS, 2026)
• Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously (Neuron, 2019)
• Labeled substance P as a neuropeptide reporter substance for enzyme activity (Journal of Pharmaceutical and Biomedical Analysis, 2020)
• Substance P plays a critical role in synaptic transmission in striatal neurons (Biochemical and Biophysical Research Communications, 2019)
• The role of Substance P in the defense line of the respiratory tract and neurological manifestations post COVID-19 infection (Frontiers in Neurology, 2023)
• Serotonin and substance P: Synergy or competition in the control of breathing (Autonomic Neuroscience, 2020)
• Substance P and thiorphan synergically enhance angiogenesis in wound healing (Tissue Engineering and Regenerative Medicine, 2016)
• The Regenerative Potential of Substance P (International Journal of Molecular Sciences, 2022)
• Role of Histamine as a Peripheral Sympathetic Neuromediator and its Interrelation with Substance P (Current Pharmaceutical Design, 2020)
• Revisiting substance P in migraine: a methodological approach inspired by anti-CGRP and anti-PACAP success (The Journal of Headache and Pain, 2025)
• Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System (Journal of Neurology & Neuromedicine, 2016)